Laurent Peyrin‐Biroulet

Délégation Centre-Est — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

136h-index85.3kcitations2.1kworks6.12yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(1575), Microscopic Colitis(1015), Eosinophilic Esophagitis(239), Autoimmune and Inflammatory Disorders(199), Immunodeficiency and Autoimmune Disorders(134)

Publications2.1k total

DOP060 Impact of baseline disease extent on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from ABTECT-1 and ABTECT-2 phase 3 trials

Journal of Crohn s and Colitis·2026

P0952 Impact of baseline Mayo endoscopic subscore on the efficacy of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the two Phase 3 ABTECT induction trials

Journal of Crohn s and Colitis·2026

P0922 Impact of obefazimod treatment on histologic and combined histologic-endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials

Journal of Crohn s and Colitis·2026Open Access

P0712 Integrated summary of safety of obefazimod in Phase 3 ABTECT induction trials

Journal of Crohn s and Colitis·2026

P0571 Wash-out period in the transition from biologics to small molecules has no impact on safety in IBD: a retrospective cohort study

Journal of Crohn s and Colitis·2026

Bowel Urgency Improvement Correlates With Clinical, Biochemical, and Intestinal Ultrasound Improvements in Inflammatory Bowel Disease: A Cross Sectional Multicenter Study

United European Gastroenterology Journal·2025Open Access

Building a healthcare data warehouse: considerations, opportunities, and challenges

2 cited

Frontiers in Digital Health·2025· 2 citedOpen Access

TL1A blockade in inflammatory bowel diseases: Clinical trials to watch

Med·2025

Prévalence du dépistage de l’ostéoporose et des fractures vertébrales ostéoporotiques chez les patients atteints de spondyloarthrite et MICI

Revue du Rhumatisme·2025

130 Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT-1 and 2)

The American Journal of Gastroenterology·2025

Efficacy and safety of risankizumab in patients with moderately to severely active Crohn’s disease: interim results from the SEQUENCE open-label extension study

Journal of Crohn s and Colitis·2025Open Access

Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease

Contemporary Clinical Trials Communications·2025Open Access

Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease

The Lancet. Gastroenterology & hepatology·2025

Benefit–risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn’s disease

Journal of Crohn s and Colitis·2025Open Access

Évaluation du risque de cancers cutanés chez les patients atteints de maladies inflammatoires chroniques : proposition d’un groupe de travail pluridisciplinaire

Annales de Dermatologie et de Vénéréologie - FMC·2025

Expert opinion on hot topics in the field of IBD

Clinics and Research in Hepatology and Gastroenterology·2025Open Access

Management of Patients with Ulcerative Proctitis: A Global Survey

1 cited

Digestive Diseases and Sciences·2025· 1 citedOpen Access

Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn’s Disease

Clinical Gastroenterology and Hepatology·2025Open Access

Long-term safety of ustekinumab in Crohn’s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data

Digestive and Liver Disease·2025Open Access

Pharmacological management of upper gastrointestinal Crohn’s disease: a systematic review

Journal of Crohn s and Colitis·2025Open Access

page 1 of 104Next →

Frequent Co-authors

Silvio Danese(24), William J. Sandborn(18), Jean‐Frédéric Colombel(10), Brian G. Feagan(10), Edward V. Loftus(10), Julián Panés(9), Geert D’Haens(8), Gert Van Assche(7), Walter Reinisch(7), Remo Panaccione(7), Stefan Schreiber(7), Bruce E. Sands(6), Édouard Louis(5), Marla C. Dubinsky(4), Toshifumi Hibi∥(4), Marc Lémann(4), Jean–Frédéric Colombel(4), Séverine Vermeire(4), Matthieu Allez(4), David T. Rubin(3)